Clinica BavieraXMAD:CBAV +0.71%100 ROA % is 23.00% as of Mar. 2026, which is 15% above its 10-year median of 19.98. GuruFocus rates XMAD:CBAV with a GF Score™ of 100/100 and a GF Value™ of €41.29 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 215 Medical Diagnostics & Research companies, Clinica Baviera ranks better than 93.49% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Clinica Baviera's annualizedNet Income for the quarter that ended in Mar. 2026 was €58.8 Mil.
Clinica Baviera's average Total Assets over the quarter that ended in Mar. 2026 was €255.7 Mil. Therefore, Clinica Baviera's annualized ROA % for the quarter that ended in Mar. 2026 was 23.00%.
The historical rank and industry rank for Clinica Baviera's ROA % or its related term are showing as below:
XMAD:CBAV'
s ROA % Range Over the Past 10 Years
Min: 12.53 Med: 19.98 Max: 21.88
Current: 18.41
During the past 13 years, Clinica Baviera's highest ROA % was 21.88%. The lowest was 12.53%. And the median was 19.98%.
XMAD:CBAV's ROA % is ranked better than 93.49% of 215
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.87
vs XMAD:CBAV: 18.41
Clinica Baviera (XMAD:CBAV) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Clinica Baviera ROA % Related Terms
Clinica Baviera ROA % Historical Data
* Premium members only.
The historical data trend for Clinica Baviera's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Clinica Baviera's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clinica Baviera ROA % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Clinica Baviera's ROA % distribution charts can be found below:
* The bar in red indicates where Clinica Baviera's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Clinica Baviera (XMAD:CBAV) has a ROA % of 23.00% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Clinica Baviera and its competitors. This is 15% above median its historical median of 19.98. Over the past decade, Clinica Baviera's ROA % has ranged from 12.53 to 21.88. According to the industry distribution chart, Clinica Baviera ranks #14 out of 215 companies in the Medical Diagnostics & Research industry, placing it in the top 6.5%.
Is Clinica Baviera's ROA % too high?
Clinica Baviera's current ROA % of 23.00% is 15% above median its 10-year median of 19.98. Over the past 10 years, this metric has ranged from a low of 12.53 to a high of 21.88. Based on the distribution chart, Clinica Baviera ranks #14 out of 215 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Clinica Baviera has a GF Score™ of 100/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Clinica Baviera's ROA % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Clinica Baviera ranks #14 out of 215 companies for ROA %. This places Clinica Baviera in the top 7% of its industry — outperforming the majority of peers. Historically, Clinica Baviera's own ROA % has ranged from 12.53 to 21.88 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Medical Diagnostics & Research company?
A good ROA % depends on the Medical Diagnostics & Research industry context. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Clinica Baviera and its competitors. Clinica Baviera's current ROA % is 23.00%, which is 15% above median its own 10-year median of 19.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clinica Baviera stock overvalued right now?
Based on GuruFocus' analysis, Clinica Baviera (XMAD:CBAV) is currently considered Significantly Overvalued. The stock's GF Value™ is €41.29, compared to a current price of €56.60 — trading 37.1% above its estimated fair value. The current ROA % is 23.00%, which is 15% above median its 10-year median of 19.98. Clinica Baviera's overall GF Score™ is 100/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Clinica Baviera (XMAD:CBAV), the current ROA % is 23.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Clinica Baviera (XMAD:CBAV) Overvalued in 2026?
Based on GuruFocus' analysis, Clinica Baviera stock appears to be overvalued.
The current stock price of €56.60 is trading 37.1% above its estimated GF Value™ of €41.29.
GuruFocus considers Clinica Baviera to be Significantly Overvalued.
Key valuation signals for XMAD:CBAV:
ROA %: 23.00% (15% above median its 10-year median of 19.98)
GF Value™: €41.29 vs. price of €56.60 (37.1% above fair value)
No single metric tells the full story. See the XMAD:CBAV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Clinica Baviera SA operates ophthalmological clinics. It is involved in the diagnosis, treatment, and monitoring of various types of ophthalmological disorders. It offers diagnosis and treatment for various eye problems such as long-sightedness, short-sightedness, astigmatism, cataracts and eye strain.
100GF Score
Get the complete analysis for XMAD:CBAV
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:CBAV has been successfully added to your 
